Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 5: 665 - 670

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.05.018

Review

Relationship between non-coding RNAs and vascular diseases of diabetes mellitus

  • Shu-jun WAN ,
  • Xiang KONG ,
  • Kun Lü
Expand
  • Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution, Wannan Medical College, Wuhu 241001, China;Central Laboratory of Yijishan Hospital, Wannan Medical College, Wuhu 241001, China

Online published: 2021-05-27

Supported by

National Natural Science Foundation of China(81472017)

Fold

Abstract

Non-coding RNAs (ncRNAs) are a class of molecules that do not encode protein. As important biological regulatory factors, they can affect the occurrence and development of vascular diseases of diabetes mellitus (DM) at the levels of transcription and post-transcription. ncRNAs mainly include microRNAs (miRNAs), long non coding RNAs (lncRNAs) and circular RNAs (circRNAs) according to their fragment sizes. miRNAs can regulate target gene expressions at the post-transcriptional level and have the potential to be their clinical markers. lncRNAs affect a variety of molecular signaling pathways. The role of lncRNAs in vascular diseases of DM has attracted increasing attention in recent years. circRNAs possess significant capabilities of gene regulation and could participate in pathological process of DM by competing with miRNAs for binding sites. To develop new ideas for the diagnosis and treatment of vascular diseases of DM, a brief review of the current research on ncRNAs and DM angiopathy is provided.

Key words： non-coding RNA (ncRNA); microRNA (miRNA); long non-coding RNA (lncRNA); diabetes mellitus (DM); vascular diseases of diabetes mellitus

Cite this article

Shu-jun WAN , Xiang KONG , Kun Lü . Relationship between non-coding RNAs and vascular diseases of diabetes mellitus[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(5) : 665 -670 . DOI: 10.3969/j.issn.1674-8115.2021.05.018

References

1 Beltrami C, Angelini TG, Emanueli C. Noncoding RNAs in diabetes vascular complications[J]. J Mol Cell Cardiol, 2015, 89: 42-50.
2 Cefalu WT, Buse JB, Tuomilehto J, et al. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: reflections from a diabetes care editors expert forum[J]. Diabetes Care, 2016, 39(7): 1186-1201.
3 Rübsam A, Parikh S, Fort P. Role of inflammation in diabetic retinopathy[J]. Int J Mol Sci, 2018, 19(4): 942.
4 Tang J, Yao DY, Yan HY, et al. The role of MicroRNAs in the pathogenesis of diabetic nephropathy[J]. Int J Endocrinol, 2019, 2019: 8719060.
5 Ahmed F, Bakhashab S, Bastaman I, et al. Anti-angiogenic miR-222, miR-195, and miR-21a plasma levels in T1DM are improved by metformin therapy, thus elucidating its cardioprotective effect: the MERIT study[J]. Int J Mol Sci, 2018, 19(10): 3242.
6 DiStefano JK. Beyond the protein-coding sequence: noncoding RNAs in the pathogenesis of type 2 diabetes[J]. Rev Diabet Stud, 2015, 12(3/4): 260-276.
7 Howangyin KY, Silvestre JS. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction[J]. Arterioscler Thromb Vasc Biol, 2014, 34(6): 1126-1135.
8 Feng J, Xing WL, Xie L. Regulatory roles of MicroRNAs in diabetes[J]. Int J Mol Sci, 2016, 17(10): 1729.
9 Paul P, Chakraborty A, Sarkar D, et al. Interplay between miRNAs and human diseases[J]. J Cell Physiol, 2018, 233(3): 2007-2018.
10 Liu TT, Hao Q, Zhang Y, et al. Effects of microRNA-133b on retinal vascular endothelial cell proliferation and apoptosis through angiotensinogen-mediated angiotensin II- extracellular signal-regulated kinase 1/2 signalling pathway in rats with diabetic retinopathy[J]. Acta Ophthalmol, 2018, 96(5): e626-e635.
11 Li EH, Huang QZ, Li GC, et al. Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene[J]. Biosci Rep, 2017, 37(2): BSR20160572.
12 Costantino S, Paneni F, Lüscher TF, et al. MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart[J]. Eur Heart J, 2016, 37(6): 572-576.
13 Zhong X, Chung ACK, Chen HY, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes[J]. Diabetologia, 2013, 56(3): 663-674.
14 Chandy M, Ishida M, Shikatani EA, et al. C-Myb regulates transcriptional activation of miR-143/145 in vascular smooth muscle cells[J]. PLoS One, 2018, 13(8): e0202778.
15 de Gonzalo-Calvo D, Cenarro A, Civeira F, et al. microRNA expression profile in human coronary smooth muscle cell-derived microparticles is a source of biomarkers[J]. Clínica E Investig En Arterioscler, 2016, 28(4): 167-177.
16 Long JY, Wang Y, Wang WJ, et al. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy[J]. J Biol Chem, 2011, 286(13): 11837-11848.
17 Badal SS, Wang Y, Long JY, et al. miR-93 regulates Msk2-mediated chromatin remodelling in diabetic nephropathy[J]. Nat Commun, 2016, 7: 12076.
18 Florijn BW, JMGJ Duijs, Levels JHM, et al. Diabetic nephropathy alters the distribution of circulating angiogenic microRNAs among extracellular vesicles, HDL, and ago-2[J]. Diabetes, 2019, 68(12): 2287-2300.
19 Cheng HS, Sivachandran N, Lau A, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways[J]. EMBO Mol Med, 2013, 5(7): 1017-1034.
20 Liu XS, Fan BY, Szalad A, et al. MicroRNA-146a mimics reduce the peripheral neuropathy in type 2 diabetic mice[J]. Diabetes, 2017, 66(12): 3111-3121.
21 Wang L, Chopp M, Lu XR, et al. miR-146a mediates thymosin β4 induced neurovascular remodeling of diabetic peripheral neuropathy in type-II diabetic mice[J]. Brain Res, 2019, 1707: 198-207.
22 de Gonzalo-Calvo D, Vilades D, Martinezcamblor P, et al. Circulating microRNAs in suspected stable coronary artery disease: a coronary computed tomography angiography study[J]. J Intern Med, 2019, 286(3): 341-355.
23 Barber JL, Zellars KN, Barringhaus KG, et al. The effects of regular exercise on circulating cardiovascular-related microRNAs[J]. Sci Rep, 2019, 9(1): 7527.
24 Al-Hayali MA, Sozer V, Durmus S, et al. Clinical value of circulating microribonucleic acids miR-1 and miR-21 in evaluating the diagnosis of acute heart failure in asymptomatic type 2 diabetic patients[J]. Biomolecules, 2019, 9(5): 193.
25 王磊,王红娜, 祖晓麟. 血浆miR-126水平与冠状动脉慢血流现象的关系[J]. 中华医学杂志, 2019, 99(17): 1323-1327.
26 Rawal S, Munasinghe PE, Shindikar A, et al. Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy[J]. Cardiovasc Res, 2017, 113(1): 90-101.
27 Seleem M, Shabayek M, Ewida HA. MicroRNAs 342 and 450 together with NOX-4 activity and their association with coronary artery disease in diabetes[J]. Diabetes Metab Res Rev, 2019, 35(5): e3130.
28 Pernomian L, Moreira JD, Gomes MS. In the view of endothelial microparticles: novel perspectives for diagnostic and pharmacological management of cardiovascular risk during diabetes distress[J]. Exp Diabetes Res, 2018, 2018: 9685205.
29 Davidovich C, Cech TR. The recruitment of chromatin modifiers by long noncoding RNAs: lessons from PRC2[J]. RNA, 2015, 21(12): 2007-2022.
30 He XY, Ou CL, Xiao YH, et al. LncRNAs: key players and novel insights into diabetes mellitus[J]. Oncotarget, 2017, 8(41): 71325-71341.
31 Salviano-Silva A, Lobo-Alves SC, de Almeida RC, et al. Besides pathology: long non-coding RNA in cell and tissue homeostasis[J]. Non-Coding RNA, 2018, 4(1): 3.
32 Zhu AD, Sun YY, Ma QJ, et al. lncRNA-ATB promotes viability, migration, and angiogenesis in human microvascular endothelial cells by sponging microRNA-195[J]. J Cell Biochem, 2019, 120(9): 14360-14371.
33 Feng YM, Chen S, Xu JR, et al. Dysregulation of lncRNAs GM5524 and GM15645 involved in high glucose induced podocyte apoptosis and autophagy in diabetic nephropathy[J]. Mol Med Rep, 2018, 18(4): 3657-3664.
34 Abdulle LE, Hao JL, Pant OP, et al. MALAT1 as a diagnostic and therapeutic target in diabetes-related complications: a promising long-noncoding RNA[J]. Int J Med Sci, 2019, 16(4): 548-555.
35 Zhang JY, Chen MC, Chen JW, et al. Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis[J]. Biosci Rep, 2017, 37(2): BSR20170036.
36 Thomas AA, Feng B, Chakrabarti S. ANRIL: a regulator of VEGF in diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2017, 58(1): 470.
37 Wang M, Wang SY, Yao D, et al. A novel long non-coding RNA CYP4B1-PS1-001 regulates proliferation and fibrosis in diabetic nephropathy[J]. Mol Cell Endocrinol, 2016, 426: 136-145.
38 Yang Y, Lv X, Fan QL, et al. Analysis of circulating lncRNA expression profiles in patients with diabetes mellitus and diabetic nephropathy: differential expression profile of circulating lncRNA[J]. Clin Nephrol, 2019, 92(1): 25-35.
39 Li X, Zeng L, Cao CW, et al. Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy[J]. Exp Cell Res, 2017, 350(2): 327-335.
40 Hu MS, Wang R, Li XB, et al. LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose-induced podocyte injury via its interplay with β-catenin[J]. J Cell Mol Med, 2017, 21(11): 2732-2747.
41 Yu W, Zhao GQ, Cao RJ, et al. LncRNA NONRATT021972 was associated with neuropathic pain scoring in patients with type 2 diabetes[J]. Behav Neurol, 2017, 2017: 2941297.
42 Fachrul M, Utomo DH, Parikesit AA. lncRNA-based study of epigenetic regulations in diabetic peripheral neuropathy[J]. Silico Pharmacol, 2018, 6(1): 1-5.
43 Pant T, Dhanasekaran A, Fang J, et al. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy[J]. BMC Cardiovasc Disord, 2018, 18(1): 1-10.
44 Wu G, Cai J, Han Y, et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis and atherosclerosis by enhancing p53 activity[J]. Circulation, 2014, 130(17): 1452-1465.
45 Reddy MA, Chen Z, Park JT, et al. Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA[J]. Diabetes, 2014, 63(12): 4249-4261.
46 Das S, Senapati P, Chen Z, et al. Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells[J]. Nat Commun, 2017, 8(1): 1467.
47 Zhang B, Wang D, Ji TF, et al. Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-κB signaling pathway in a rat model[J]. Oncotarget, 2017, 8(10): 17347-17359.
48 Zaiou M. CircRNAs signature as potential diagnostic and prognostic biomarker for diabetes mellitus and related cardiovascular complications[J]. Cells, 2020, 9(3): 659.
49 Yan QJ, He XY, Kuang GY, et al. CircRNA cPWWP2A: an emerging player in diabetes mellitus[J]. J Cell Commun Signal, 2020, 14(3): 351-353.
50 Zhang SJ, Chen X, Li CP, et al. Identification and characterization of circular RNAs as a new class of putative biomarkers in diabetes retinopathy[J]. Investig Ophthalmol Vis Sci, 2017, 58(14): 6500-6509.
51 Liu C, Yao MD, Li CP, et al. Silencing of circular RNA-ZNF609 ameliorates vascular endothelial dysfunction[J]. Theranostics, 2017, 7(11): 2863-2877.
52 Hu W, Han Q, Zhao L, et al. Circular RNA circRNA_15698 aggravates the extracellular matrix of diabetic nephropathy mesangial cells via miR-185/TGF-β1[J]. J Cell Physiol, 2019, 234(2): 1469-1476.
53 Liu HF, Wang X, Wang ZY, et al. Circ_0080425 inhibits cell proliferation and fibrosis in diabetic nephropathy via sponging miR-24-3p and targeting fibroblast growth factor 11[J]. J Cell Physiol, 2020, 235(5): 4520-4529.
54 Wang L, Luo TY, Bao ZH, et al. Intrathecal circHIPK3 shRNA alleviates neuropathic pain in diabetic rats[J]. Biochem Biophys Res Commun, 2018, 505(3): 644-650.
55 Tang CM, Zhang M, Huang L, et al. CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts[J]. Sci Rep, 2017, 7: 40342.
56 Zhou B, Yu JW. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1[J]. Biochem Biophys Res Commun, 2017, 487(4): 769-775.
57 Yang F, Li A, Qin Y, et al. A novel circular RNA mediates pyroptosis of diabetic cardiomyopathy by functioning as a competing endogenous RNA[J]. Mol Ther Nucleic Acids, 2019, 17: 636-643.
58 Xu HY, Guo S, Li W, et al. The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells[J]. Sci Rep, 2015, 5: 12453.
59 Li CY, Zhao L, Jiang W, et al. Correct microarray analysis approaches in 'Hsa-circRNA11783-2 in peripheral blood is correlated with coronary artery disease and type 2 diabetes mellitus'[J]. Diabetes Vasc Dis Res, 2018, 15(1): 92-93.
Options
Outlines

/

〈 〉